Karuna Therapeutics, Inc. – NASDAQ:KRTX
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Karuna Therapeutics stock price monthly change
+0.57%
month
Karuna Therapeutics stock price quarterly change
+88.58%
quarter
Karuna Therapeutics stock price yearly change
+70.89%
year
Karuna Therapeutics key metrics
Market Cap | 12.59B |
Enterprise value | 6.00B |
P/E | -21.48 |
EV/Sales | 564.84 |
EV/EBITDA | -23.14 |
Price/Sales | 587.69 |
Price/Book | 5.55 |
PEG ratio | 0.27 |
EPS | -11.39 |
Revenue | N/A |
EBITDA | -494.33M |
Income | -422.18M |
Revenue Q/Q | -100% |
Revenue Y/Y | -93.85% |
Profit margin | -2597.88% |
Oper. margin | -2723.29% |
Gross margin | 0% |
EBIT margin | -2723.29% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKaruna Therapeutics stock price history
Karuna Therapeutics stock forecast
Karuna Therapeutics financial statements
| Mar 2023 | 654K | -86.08M | -13162.39% |
|---|---|---|---|
| Jun 2023 | 0 | -103.16M | |
| Sep 2023 | 0 | -119.11M | |
| Dec 2023 | 0 | -113.82M |
| Sep 2023 | 0 | -119.11M | |
|---|---|---|---|
| Dec 2023 | 0 | -113.82M | |
| Sep 2025 | 44.30M | -75.75M | -171% |
| Dec 2025 | 56.94M | -62.09M | -109.04% |
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 1516168000 | 28.03M | 1.85% |
|---|---|---|---|
| Jun 2023 | 1472103000 | 52.54M | 3.57% |
| Sep 2023 | 1385097000 | 62.78M | 4.53% |
| Dec 2023 | 1336209000 | 81.97M | 6.13% |
| Mar 2023 | -100.62M | -27.49M | 442.45M |
|---|---|---|---|
| Jun 2023 | -64.13M | -253.58M | 18.39M |
| Sep 2023 | -109.99M | 28.31M | 2.65M |
| Dec 2023 | -111.05M | 92.44M | 19.86M |
Karuna Therapeutics alternative data
| Aug 2023 | 210 |
|---|---|
| Sep 2023 | 210 |
| Oct 2023 | 210 |
| Nov 2023 | 210 |
| Dec 2023 | 210 |
| Jan 2024 | 210 |
| Feb 2024 | 210 |
| Mar 2024 | 339 |
| Apr 2024 | 339 |
| May 2024 | 339 |
| Jun 2024 | 339 |
| Jul 2024 | 339 |
Karuna Therapeutics other data
56.39%
-43.61%
of KRTX is owned by hedge funds
159
-86
17.83M
-16.74M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 0 | 5000 |
| Apr 2023 | 0 | 51000 |
| May 2023 | 0 | 9000 |
| Jul 2023 | 0 | 14810 |
| Aug 2023 | 0 | 20310 |
| Sep 2023 | 0 | 18809 |
| Oct 2023 | 0 | 5000 |
| Nov 2023 | 0 | 5000 |
| Dec 2023 | 0 | 10000 |
| Jan 2024 | 0 | 15000 |
| Feb 2024 | 0 | 5000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BRANNAN STEPHEN K. officer: Chief Me.. | Common Stock | 5,000 | $111.97 | $559,850 | ||
Sale | BRANNAN STEPHEN K. officer: Chief Me.. | Common Stock | 4,182 | $316.05 | $1,321,721 | ||
Option | BRANNAN STEPHEN K. officer: Chief Me.. | Common Stock | 2,500 | $5.45 | $13,625 | ||
Sale | BRANNAN STEPHEN K. officer: Chief Me.. | Common Stock | 818 | $316.56 | $258,946 | ||
Option | BRANNAN STEPHEN K. officer: Chief Me.. | Option (right to buy) | 5,000 | $111.97 | $559,850 | ||
Option | BRANNAN STEPHEN K. officer: Chief Me.. | Option (right to buy) | 2,500 | $5.45 | $13,625 | ||
Option | BRANNAN STEPHEN K. officer: Chief Me.. | Common Stock | 9,696 | $111.97 | $1,085,661 | ||
Option | BRANNAN STEPHEN K. officer: Chief Me.. | Option (right to buy) | 9,696 | $111.97 | $1,085,661 | ||
Option | BRANNAN STEPHEN K. officer: Chief Me.. | Common Stock | 5,304 | $131.64 | $698,219 | ||
Sale | BRANNAN STEPHEN K. officer: Chief Me.. | Common Stock | 15,000 | $316.81 | $4,752,150 |
| Patent |
|---|
Application Filling date: 3 Feb 2022 Issue date: 19 May 2022 |
Application Filling date: 21 Feb 2020 Issue date: 12 May 2022 |
Application Filling date: 7 Jan 2021 Issue date: 17 Jun 2021 |
Application Filling date: 4 Feb 2021 Issue date: 27 May 2021 |
Application Filling date: 17 Nov 2020 Issue date: 20 May 2021 |
Application Filling date: 16 Nov 2020 Issue date: 20 May 2021 |
Grant Utility: Compositions and methods for treating disorders ameliorated by muscarinic receptor activation Filling date: 27 Sep 2019 Issue date: 2 Mar 2021 |
Grant Utility: Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation Filling date: 21 May 2020 Issue date: 23 Feb 2021 |
Application Filling date: 21 May 2020 Issue date: 17 Sep 2020 |
Application Filling date: 27 Sep 2019 Issue date: 2 Apr 2020 |
| Quarter | Transcript |
|---|---|
| Q3 2023 5 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 5 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 6 May 2023 | Q1 2023 Earnings Call Transcript |
Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine
Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started
Karuna Therapeutics: KarXT Could Become A New Standard Of Care In Schizophrenia
Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It
Karuna: NDA Filing Q3 Of 2023 And Expanded Potential With KarXT
Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade)
Biopharma Exposure In SVB Financial Group And Investor Strategy
Karuna Therapeutics: Best Nearby Biotech Cap-Gain Wealth Builder Stock
Neurocrine Biosciences: Stencil In These Important Dates
-
When is Karuna Therapeutics's next earnings date?
Unfortunately, Karuna Therapeutics's (KRTX) next earnings date is currently unknown.
-
Does Karuna Therapeutics pay dividends?
No, Karuna Therapeutics does not pay dividends.
-
How much money does Karuna Therapeutics make?
Karuna Therapeutics has a market capitalization of 12.59B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 93.85% to 654K US dollars.
-
What is Karuna Therapeutics's stock symbol?
Karuna Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "KRTX".
-
What is Karuna Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Karuna Therapeutics?
Shares of Karuna Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Karuna Therapeutics's key executives?
Karuna Therapeutics's management team includes the following people:
- Dr. Steven M. Paul M.D. Chief Executive Officer, Pres & Chairman(age: 74, pay: $871,050)
- Dr. Andrew Craig Miller Co-Founder & Chief Operating Officer(age: 43, pay: $646,550)
- Dr. Stephen K. Brannan Chief Medical Officer(age: 69, pay: $624,550)
- Dr. Troy A. Ignelzi Chief Financial Officer & Sec.(age: 57, pay: $596,550)
-
Is Karuna Therapeutics founder-led company?
Yes, Karuna Therapeutics is a company led by its founder Dr. Andrew Craig Miller.
-
How many employees does Karuna Therapeutics have?
As Jul 2024, Karuna Therapeutics employs 339 workers.
-
When Karuna Therapeutics went public?
Karuna Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 28 Jun 2019.
-
What is Karuna Therapeutics's official website?
The official website for Karuna Therapeutics is karunatx.com.
-
Where are Karuna Therapeutics's headquarters?
Karuna Therapeutics is headquartered at 99 High Street, Boston, MA.
-
How can i contact Karuna Therapeutics?
Karuna Therapeutics's mailing address is 99 High Street, Boston, MA and company can be reached via phone at 857 449 2244.
Karuna Therapeutics company profile:
Karuna Therapeutics, Inc.
karunatx.comExchange:
NASDAQ
Full time employees:
339
Industry:
Biotechnology
Sector:
Healthcare
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
99 High Street
Boston, MA 02110
Boston, MA 02110
CIK: 0001771917
ISIN: US48576A1007
CUSIP: 48576A100
